{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T02:43:39Z","timestamp":1771987419062,"version":"3.50.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.31744","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T15:34:32Z","timestamp":1635348872000},"page":"e2131744","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020"],"prefix":"10.1001","volume":"4","author":[{"given":"Satya","family":"Das","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody L.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina D.","family":"Arhin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Chan","sequence":"additional","affiliation":[{"name":"Dana Faber Cancer Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Halperin","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"LaFerriere","sequence":"additional","affiliation":[{"name":"Biomedical Library, Vanderbilt University, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"Sunybrook Health Sciences Centre, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Kunz","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"10","key":"zoi210907r1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi210907r2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000337662","article-title":"Quality of clinical trials in gastroenteropancreatic neuroendocrine tumours.","volume":"96","author":"Walter","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"12","key":"zoi210907r3","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"zoi210907r4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.v76.2","article-title":"The 2019 WHO classification of tumours of the digestive system.","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"6","key":"zoi210907r5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"10022","key":"zoi210907r6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"zoi210907r7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors.","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi210907r8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.","volume":"29","author":"Kulke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi210907r9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000454761","article-title":"Neuroendocrine cancer, therapeutic strategies in G3 cancers.","volume":"95","author":"Rinke","year":"2017","journal-title":"Digestion"},{"key":"zoi210907r10","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211018047","article-title":"Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.","volume":"13","author":"Das","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"zoi210907r11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/ERC-17-0197","article-title":"Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.","volume":"24","author":"Imaoka","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"zoi210907r12","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1097\/RLU.0000000000001457","article-title":"The impact of radiological response to peptide receptor radionuclide therapy on overall survival in patients with metastatic midgut neuroendocrine tumors.","volume":"42","author":"Yalchin","year":"2017","journal-title":"Clin Nucl Med"},{"key":"zoi210907r13","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2018.36.15_suppl.4004","article-title":"A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).","volume":"36","author":"Kunz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi210907r14","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju229","article-title":"Adult cancer clinical trials that fail to complete: an epidemic?","volume":"106","author":"Stensland","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"zoi210907r15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology.","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2785532\/das_2021_oi_210907_1634737264.71022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T15:34:36Z","timestamp":1635348876000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2785532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.31744","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]}}}